These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25335532)

  • 1. Targeted lipid nanoparticles for antisense oligonucleotide delivery.
    Petrilli R; Eloy JO; Marchetti JM; Lopez RF; Lee RJ
    Curr Pharm Biotechnol; 2014; 15(9):847-55. PubMed ID: 25335532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate receptor-targeted lipid-albumin nanoparticles (F-LAN) for therapeutic delivery of an Akt1 antisense oligonucleotide.
    Li H; Liu Y; Chen L; Liu Q; Qi S; Cheng X; Lee YB; Ahn CH; Kim DJ; Lee RJ
    J Drug Target; 2018; 26(5-6):466-473. PubMed ID: 29376449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of antisense oligonucleotide using polyethylenimine-based lipid nanoparticle modified with cell penetrating peptide.
    Yang S; Wang D; Sun Y; Zheng B
    Drug Deliv; 2019 Dec; 26(1):965-974. PubMed ID: 31544540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer.
    Cheng X; Liu Q; Li H; Kang C; Liu Y; Guo T; Shang K; Yan C; Cheng G; Lee RJ
    Pharm Res; 2017 Feb; 34(2):310-320. PubMed ID: 27896589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of Antisense Oligonucleotide LOR-2501 Using Transferrin-conjugated Polyethylenimine-based Lipid Nanoparticle.
    Zheng B; Yang S; Tian Q; Xie Y; Zhang S; Lee RJ
    Anticancer Res; 2019 Apr; 39(4):1785-1793. PubMed ID: 30952718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled delivery of antisense oligonucleotides: a brief review of current strategies.
    Zhao X; Pan F; Holt CM; Lewis AL; Lu JR
    Expert Opin Drug Deliv; 2009 Jul; 6(7):673-86. PubMed ID: 19552611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Polyethylenimine-Containing and Transferrin-Conjugated Lipid Nanoparticle System for Antisense Oligonucleotide Delivery to AML.
    Yuan Y; Zhang L; Cao H; Yang Y; Zheng Y; Yang XJ
    Biomed Res Int; 2016; 2016():1287128. PubMed ID: 27034925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide vectors for the nonviral delivery of nucleic acids.
    Hoyer J; Neundorf I
    Acc Chem Res; 2012 Jul; 45(7):1048-56. PubMed ID: 22455499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery.
    Thanki K; Papai S; Lokras A; Rose F; Falkenberg E; Franzyk H; Foged C
    Pharm Res; 2019 Jan; 36(3):37. PubMed ID: 30623253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery systems for oligonucleotide therapeutics.
    Yu B; Zhao X; Lee LJ; Lee RJ
    AAPS J; 2009 Mar; 11(1):195-203. PubMed ID: 19296227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transferrin- and folate-modified, double-targeted nanocarriers for gene delivery.
    Jing F; Li D; Xu W; Liu Y; Wang K; Sui Z
    Pharm Biol; 2014 May; 52(5):570-4. PubMed ID: 24256214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.
    Cheng X; Lee RJ
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):129-137. PubMed ID: 26900977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells.
    Ginobbi P; Geiser TA; Ombres D; Citro G
    Anticancer Res; 1997; 17(1A):29-35. PubMed ID: 9066627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-Based Nanoparticle Functionalization with Coiled-Coil Peptides for
    Aschmann D; Knol RA; Kros A
    Acc Chem Res; 2024 Apr; 57(8):1098-1110. PubMed ID: 38530194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
    Peng J; He X; Wang K; Tan W; Li H; Xing X; Wang Y
    Nanomedicine; 2006 Jun; 2(2):113-20. PubMed ID: 17292123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-Albumin Nanoparticles (LAN) for Therapeutic Delivery of Antisense Oligonucleotide against HIF-1α.
    Li H; Quan J; Zhang M; Yung BC; Cheng X; Liu Y; Lee YB; Ahn CH; Kim DJ; Lee RJ
    Mol Pharm; 2016 Jul; 13(7):2555-62. PubMed ID: 27253378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery.
    Chan DP; Deleavey GF; Owen SC; Damha MJ; Shoichet MS
    Biomaterials; 2013 Nov; 34(33):8408-15. PubMed ID: 23932248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid conjugated oligonucleotides: a useful strategy for delivery.
    Raouane M; Desmaële D; Urbinati G; Massaad-Massade L; Couvreur P
    Bioconjug Chem; 2012 Jun; 23(6):1091-104. PubMed ID: 22372953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into polysaccharide-based nanostructured delivery systems in breast cancer: Possible application of antisense oligonucleotides in breast cancer therapy.
    Shayegh F; Türk Z; Armani A; Zarghami N
    Int J Biol Macromol; 2024 Jun; 272(Pt 2):132890. PubMed ID: 38848829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
    Li H; Xu S; Quan J; Yung BC; Pang J; Zhou C; Cho YA; Zhang M; Liu S; Muthusamy N; Chan KK; Byrd JC; Lee LJ; Marcucci G; Lee RJ
    Mol Pharm; 2015 Jun; 12(6):2010-8. PubMed ID: 25871632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.